IDEAYA Biosciences (IDYA) drew fresh attention after promoting Dr. Michael White to President, Research and Development on 28 September 2026. The move highlights how leadership decisions intersect with the company’s precision oncology ambitions.
Recent trading paints a mixed picture for IDEAYA Biosciences. The share price has risen 12.91% year to date and the 1-year total shareholder return sits at 40.57%. However, the 30-day share price return is down 4.71% as investors reassess risk and execution after earlier gains.
Scan other precision-oncology opportunities moving on fresh trial data and leadership shifts by reviewing our curated list of 37 healthcare AI stocks alongside IDEAYA Biosciences.
IDEAYA Biosciences now trades at about $38 while published fair value estimates cluster much higher. Is that a meaningful margin of safety, or a signal that expectations already stretch the story?
Most Popular Narrative: 41.2% Undervalued
Against a last close of about $38, the most followed narrative on IDEAYA Biosciences points to a Fair Value of $65, which places the current pricing well below what optimistic followers of the story consider reasonable for the pipeline.
The potential approval and commercial launch of darovasertib in HLA-A2 negative metastatic uveal melanoma, after a registrational trial met its primary endpoint and entered FDA Real-Time Oncology Review, could open IDEAYA Biosciences to its first product revenue stream and start to shift the company’s earnings profile away from being entirely expense driven.
See why 0 investors see IDEAYA Biosciences as 41% undervalued.
Result: Fair Value of $65 (UNDERVALUED)
Still, the bullish IDEAYA Biosciences story frays quickly if darovasertib encounters challenges at the FDA or if IDE849 fails to deliver in extensive stage small cell lung cancer.
Find out about the key risks to this IDEAYA Biosciences narrative.
Another View: Multiples Put a Different Price on IDEAYA Biosciences
That 41.2% discount to a $65 fair value leans heavily on optimistic growth and margin assumptions. On a simpler yardstick, IDEAYA Biosciences trades on a P/S of 15.8x, richer than both peers at 14.5x and the US Biotechs average at 12.1x, and far above a fair ratio of 2.6x. Is the premium a cushion for future success or a warning that enthusiasm already runs hot?
Before leaning on any single target or story, it helps to see what the numbers imply across different yardsticks, including the fair ratio the market could eventually move toward, in the full breakdown behind See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed signals around IDEAYA Biosciences can feel confusing, so consider reviewing the full risk and reward spread yourself with 2 key rewards and 1 important warning sign.
Looking for more investment ideas beyond IDEAYA Biosciences?
Do not stop with IDEAYA Biosciences if you want a broader watchlist. Use the Simply Wall Street Screener to quickly surface fresh opportunities that match your style.
- Target long term value hunters by reviewing a focused list built from 32 high quality undervalued stocks that combine appealing pricing with stronger fundamentals.
- Strengthen capital preservation goals and examine 30 resilient stocks with low risk scores that score well on resilience and balance sheet quality.
- Spot early-stage potential and scan 7 elite penny stocks with strong financials where financials look more robust than the share price implies.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com